Renal effects of levosimendan: a consensus report
Clicks: 160
ID: 271562
2013
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
2.7
/100
9 views
9 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart fail …
| Reference Key |
mb2013cardiovascularrenal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yilmaz MB;Grossini E;Silva Cardoso JC;Édes I;Fedele F;Pollesello P;Kivikko M;Harjola VP;Hasslacher J;Mebazaa A;Morelli A;le Noble J;Oldner A;Oulego Erroz I;Parissis JT;Parkhomenko A;Poelzl G;Rehberg S;Ricksten SE;Rodríguez Fernández LM;Salmenperä M;Singer M;Treskatsch S;Vrtovec B;Wikström G;; |
| Journal | cardiovascular drugs and therapy |
| Year | 2013 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
animals
humans
pubmed abstract
nih
national institutes of health
national library of medicine
Cardiotonic Agents / pharmacology*
kidney / drug effects*
simendan
hydrazones / pharmacology*
pyridazines / pharmacology*
pmid:23929366
pmc3830192
doi:10.1007/s10557-013-6485-6
mehmet b yilmaz
elena grossini
gerhard wikström
kidney / physiology
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.